Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitis

Michael J. Cork; Peck Y. Ong; Simon G. Danby; Robert A. Byers; Stephen J. Matcher; Oludolapo S. Katibi; Kirsty Brown; Paul V. Andrew; Abigail Pinnock; Anna Poyner; Laura Johnson; Stuart Gormley; Alison Hyde; Marco Ramirez-Gama; Shannon Garcia; Patricia A. Taylor; Gabriel Bologna; Amy H. Praestgaard; Joseph Zahn; Annie Zhang; Donald Y.M. Leung

doi:10.1016/j.anai.2026.01.008

Key Points

Dupilumab treatment restores the epithelial barrier in both lesional and nonlesional skin.
The restoration of the barrier occurs in children with atopic dermatitis over a specified treatment duration.
Observational analysis measured skin barrier integrity and inflammation reduction in affected areas.
Highlights the potential for dupilumab to improve skin health in pediatric patients with atopic dermatitis.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Treatment with dupilumab restores the epithelial barrier in skin lesions of children with atopic dermatitis, indicating potential for improved skin health.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cork et al. (2026) studied this question.

synapsesocial.com/papers/69a75afbc6e9836116a2183c https://doi.org/10.1016/j.anai.2026.01.008

View Full Paper

Ask AI

Bookmark

Share

Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitis

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitis

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading